Light Sciences Oncology, a Bellevue, WA-based developer of cancer drugs, said it has completed enrollment of 200 patients with liver tumors in a clinical trial. The goal of the study is to see whether patients live longer after they get LitX. The company’s treatment is designed to use a light-emitting diode, threaded inside a tumor, to activate a drug to kill tumors within its wavelength. If the trial reaches it goal, the company plans to ask regulators in the U.S. and Europe for marketing approval in 2009.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
